Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of CHXCART01 in Pediatric R/R CD19+ ALL or Lymphoma
NCT06866873Recruiting
- Sponsor
- Hong Kong Children’s Hospital
- Start
- May 2024
- Primary completion
- Dec 2037
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CHXCART01 in acute lymphoblastic leukemia (ALL) and B cell lymphoma, sponsored by Hong Kong Children’s Hospital. Primary endpoints: Complete Response Rate at 1 month, Overall Response Rate at 3 months and 1 more. Started May 2024; status: recruiting.
02
Drugs
CHXCART01
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT06866873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866873.